Ascendis Application to FDA for the Treatment of Adult Growth Hormone Deficiency

 Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD).

https://www.globenewswire.com/news-release/2024/09/30/2955194/0/en/Ascendis-Pharma-Announces-Submission-of-Supplemental-Biologics-License-Application-to-FDA-for-TransCon-hGH-for-the-Treatment-of-Adults-with-Growth-Hormone-Deficiency.html